Meeting Banner
Abstract #3593

1H MRS Reveals GABA and Glutamatergic Compound Elevations in Subjects at Ultra-High Risk for Schizophrenia

Camilo de la Fuente-Sandoval1, Pablo L. Ortiz2, Xiangling Mao3, Patricia Alavarado-Alanis4, Oscar Rodrguez-Mayoral5, Francisco Reyes-Madrigal4, Ariel Graff-Guerrero6, Rodolfo Solis-Vivanco7, Rafael Favila8, Dikoma C. Shungu3

1Neuropsychiatry & Laboratory of Experimental Psychiatry, Instituto Nacional de Neurologa y Neurociruga (INNN), Mexico City, Distrito Federal, Mexico; 2Education, INNN, Mexico City, Distrito Federal, Mexico; 3Radiology, Weill Cornell Medical College, New York, NY, United States; 4Laboratory of Experimental Psychiatry, INNN, Mexico City, Distrito Federal, Mexico; 5Early Psychosis Intervention, Hospital Fray Bernardino Alvarez, Mexico City, Distrito Federal, Mexico; 6Multimodal Neuroimaging Schizophrenia Group, Centre for Addiction and Mental Health, Toronto, ON, Canada; 7Laboratory of Neuropsychology, INNN, Mexico City, Distrito Federal, Mexico; 8MR Advanced Applications, GE Healthcare, Mexico City, Distrito Federal, Mexico


In the present study, 1H MRS was used to investigate potential dysregulations of GABA and glutamatergic compounds in subjects at ultra-high risk (UHR) for schizophrenia compared to healthy controls, and found higher levels of both neurotransmitters in the striatum and medial prefrontal cortex of the UHR group.